Genentech RTP Advanced Biomanufacturing Facility Groundbreaking

United States

Deal value: $2,000,000,000

Genentech broke ground on a new advanced biomanufacturing facility in Research Triangle Park, North Carolina, designed for large-scale biologics production and flexible cleanroom operations.

The core motivation is to expand Genentech’s biomanufacturing capacity for next-generation metabolic medicines, particularly obesity treatments, leveraging the strategic location of Research Triangle Park for its skilled workforce and proximity to other life sciences firms. The investment aligns with Roche’s $50 billion U.S. commitment to manufacturing, infrastructure, and R&D, aiming to accelerate delivery of innovative therapies and strengthen supply chain resilience. The timing reflects surging demand for biologics, policy incentives for domestic manufacturing, and the need for flexible, scalable production platforms.